Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesStevens-Johnson Syndrome Induced by Combination of Imatinib and Allopurinol
Chemotherapy, 05/13/09
Hsieh HJ et al. - An 82-year-old female patient who had a diagnosis of chronic myeloid leukemia was initially treated with imatinib 200 mg/day and allopurinol 100 mg for 42 days, and had a satisfactory hematological response. The dose of imatinib was adjusted to 400 mg/day for 14 days. After two weeks, she developed SJS and was transferred to the intensive care unit for further treatment because her general condition had deteriorated.
Related Articles
Improved early event-free survival with imatinib in philadelphia chromosome-positive acute lymphoblastic leukemia: a childrens oncology group study
Journal of Clinical Oncology, 10/09/09
Relevance Score: 48%
Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients
Current Medical Research and Opinion, 11/17/09
Relevance Score: 46%
Effect of allopurinol versus urate oxidase on methotrexate pharmacokinetics in children with newly diagnosed acute lymphoblastic leukemia
Cancer, 10/26/09
Relevance Score: 46%
Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate
Cancer, 11/06/09
Relevance Score: 44%
Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial
Haematologica, 10/07/09
Relevance Score: 43%
Today in Leukemia/Lymphoma...keeping you current
Receive free subspecialty "5-minute updates" via email
Vascular endothelial growth factor-C (VEGF-C) promotes angiogenesis by induction of COX-2 in leukemic cells via the VEGF-R3/JNK/AP-1 pathway
Carcinogenesis, 12/15/09
Nonpegylated liposomal doxorubicin (MyocetTM) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): Results from the phase II EUR018 trial
Annals of Oncology, 12/15/09
The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant Hodgkins lymphoma
European Journal of Haematology, 12/15/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme
Journal of Neuro-Oncology, 12/15/09
Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines
Cancer Chemotherapy and Pharmacology, 12/15/09
Intensive chemotherapy improves survival in pediatric high-grade glioma after gross total resection: results of the HIT-GBM-C protocol
Cancer, 12/15/09
Today in Side Effects...keeping you current
Receive free subspecialty "5-minute updates" via email
Cardiotoxicity of Anticancer Drugs: The Need for Cardio-Oncology and Cardio-Oncological Prevention
Journal of the National Cancer Institute, 12/15/09
Dermatologic Infections in Cancer Patients Treated With Epidermal Growth Factor Receptor Inhibitor Therapy
Journal of the National Cancer Institute, 12/15/09
Palonosetron for the prevention of chemotherapy-induced nausea and vomiting: Approval and efficacy
Cancer Management and Research, 12/15/09
Sponsor
Article Search
Sponsor
Sponsor